Navigation Links
Exenatide Once Monthly Showed Positive Results in Phase 2 Study
Date:3/10/2011

emic control," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "Based on the encouraging results of this study, we plan to proceed with regulatory interactions to outline the next steps for this important program."

More than 90 percent of patients overall completed the study. The most common adverse events among the exenatide once monthly treatment groups were headache and nausea. Headache and diarrhea were most common among the once-weekly BYDUREON group. No major or minor hypoglycemia was reported in the study.

Exenatide once monthly is a new, extended-release formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which is given twice daily. Exenatide once monthly is based on the same Medisorb® microsphere technology used in BYDUREON.

Study Design

This phase 2, randomized, open-label study included 121 adults with type 2 diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, Actos® (pioglitazone), or both.  Subjects were randomized to receive either 2 mg weekly subcutaneous injections of BYDUREON or subcutaneous injections of exenatide once monthly at a low, medium or high dose, each administered once every four weeks, for a total of 20 weeks.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(i, ii)  Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
5. New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
6. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
7. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. BioProcess International Launches Monthly Asia-Pacific eNewsletter
10. Technology PR Boutique Launches PRTechConnect to Help Tech Startups Restart Economy with Industry's First $999 Monthly Service
11. RSB Spine, LLC, Announces Record Second-Quarter 2010 Revenue and Monthly Sales Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)... month, executives from clinical trial marketing firm BBK Worldwide will ... Patient-Centered Clinical Trials 2014 , to be held at the ... 4-5. Patient recruitment experts Bonnie A. Brescia , ... insights on the benefits of employing an effective patient engagement ... to mobile apps – can be used to drive study ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the ... of its common stock at $4.05 per share, ... on December 12, 2007, for,approximately $45 million in ... $50 million if the underwriters,over-allotment option described below ...
... 13 Synosia Therapeutics today,announced the appointment of ... officer, effective immediately., Dr Blanc, who will ... joins from Syngenta, where he created and led ... and an,experienced biotech entrepreneur, Dr. Blanc helped biotech ...
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today ... webcast to provide an update on indiplon Thursday,morning, December ... a.m. Eastern,Time (6:00 a.m. Pacific Time)., Participants can ... 785-424-1071 (International) using the conference,ID: NEURO12. The call can ...
Cached Biology Technology:Anesiva Raises $45 Million in Common Stock Offering 2Synosia Therapeutics Announces Appointment of Chief Business Officer 2
(Date:8/31/2014)... Montral, August 31, ... Nature Neuroscience journal by, Sylvain Williams, PhD, and his ... University Institute and McGill University, opens the door towards better ... as well of the role of an essential element of ... In 2009, they developed a unique approach namely, the ...
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... MADISON Failing to see the forest for ... declining health of Wisconsin,s forest ecosystems. Even areas ... as forests are increasingly fragmented by roads and development, ... fields, housing tracts, and strip malls, say University of ...
... rings are acclaimed in representing natural climate archives. ... growth of these annual rings depend mainly on temperature ... slight seasonal variations, the correlation is not so ... for Geosciences and their colleagues of the Australian National ...
... Versartis, Inc., an emerging company developing novel biologics ... presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) ... (IL-1ra-rPEG) for treatment of type 1 and type 2 ... DC. Versartis, through a unique licensing agreement with Amunix, ...
Cached Biology News:Isolated forest patches lose species, diversity 2Isolated forest patches lose species, diversity 3Australia's climate: Drought and flooding in annual rings of tropical trees 2Versartis presents positive preclinical data on 2 product candidates at ENDO 09 2
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
BD IMagnet 1 each...
Biology Products: